GLP-1 Advisor | One Day MD

The obesity-drug market has entered a new phase. Eli Lilly and Novo Nordisk remain central to the global obesity-treatment market, but the competitive landscape in 2026 is no longer simply a two-company race between tirzepatide and semaglutide. Oral GLP-1 therapies are now commercial products. Next-generation dual and triple agonists have generated substantial clinical weight-loss results. Amylin-based medicines have moved into late-stage development. Long-acting therapies are testing less-frequent dosing, while combination strategies are attempting to address multiple biological pathways simultaneously. Important: Clinical-stage drugs discussed in this article are investigational unless explicitly identified as approved. Weight-loss percentages reported from different clinical trials should not be interpreted as direct head-to-head comparisons unless the drugs were tested against each other in the same randomized trial. Many figures below come from company-reported topli...

Does retatrutide cause muscle loss? The available evidence suggests that retatrutide-associated weight loss includes a reduction in lean mass, as occurs with other effective obesity treatments. However, the available studies do not establish how much actual skeletal muscle an individual will lose, whether the loss affects muscle function, or how much can be prevented through nutrition and exercise. In a published Phase 2 body-composition substudy involving adults with type 2 diabetes, researchers observed substantial fat-mass reductions alongside reductions in lean mass. The results do not show that retatrutide uniquely damages muscle, but they also do not justify assuming that very large weight losses will preserve muscle automatically. The practical priority is to pursue fat loss while preserving strength, physical function, adequate nutrition, and as much useful muscle as possible . Evidence updated October 2026. This article is educational and is not a substitute for ind...